Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008


Toronto Stock Exchange Symbol: MS

- US$10 million received based on the positive review of interim

analysis for international pivotal multiple sclerosis trial -

EDMONTON, Sept. 22 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.

To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.

"We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, President and CEO of BioMS Medical. "We look forward to completing the MAESTRO-01 trial and reviewing the complete data set in the second half of 2009."

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 FemCap ... women,s health announces its receipt of a patent No: ... menstrual cup has also received FDA clearance in the ... and the CE in Europe. This patent is related to ... with this issuance, the company is releasing FemmyCycle Teen, ...
(Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 ... communications (UC) and collaboration company is dedicated to ... data connectivity needs. Julie Power, a ... team to ensure collaboration solutions stays connected and ... response to the increased movement of businesses to ...
(Date:9/30/2014)... September 30, 2014 Back in the 1970’s, ... square feet. per employee, which included space for circulation and ... says Jeff Howell, partner at Nidea Corporate Real Estate ... Toronto. “By the year 2000, however, 250 square feet ... that number come down to 175 to 225 square feet, ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3
... Olive Branch Fund: A Thisbe and Noah Scott Legacy, ... today announced its first funding award to Kevin Eggan, ... at Harvard University.  The award will support Dr. Eggan,s ... that affect it.  Dr. Eggan is a leading researcher ...
... PRINCETON, N.J., June 29, 2011 PharmaNet Development Group, Inc. ... its cash tender offer and consent solicitation (the "Offer") for ... Notes due 2017 (the "Notes"), it has elected to extend ... York City time, on July 6, 2011, unless extended or ...
... Associates® - San Francisco, a specialized executive search firm ... arena, welcomes Eduard Alberts, Ph.D. as Vice President and ... of experience and success in the life sciences industry, ... companies and a wide array of cultures. His prior ...
Cached Biology Technology:The Olive Branch Fund Announces Funding Award to Harvard Researcher 2PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation 2PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation 3Eduard Alberts, Ph.D. Joins Sanford Rose Associates - San Francisco 2
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... penguins in Antarctica than was previously thought, according to ... of researchers using high-resolution satellite mapping technology. This first-ever ... important benchmark for monitoring the impact of environmental change ... from the University of Minnesota Polar Geospatial Center co-authored ...
... press release is available in German . , ... beings in their own right. This changed about one billion years ... cells. Since then, they have lost much of their autonomy. As ... into the cell nucleus; today, chloroplasts would no longer be able ...
... Calif.All animals seem to have ways of exchanging informationmonkeys ... and fireflies light up their bellies to attract mates. ... among the most abundant animals on the planet, little ... led by California Institute of Technology (Caltech) biologists has ...
Cached Biology News:Scientists complete first-ever emperor penguin count from space 2Direct transfer of plant genes from chloroplasts into the cell nucleus 2Decoding worm lingo 2Decoding worm lingo 3
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
Biology Products: